EQ Equillium
- 1.7100
- -0.1000-5.52%
- 1.7900
- +0.0800+4.68%
Equillium News
Short Interest on Energy Stocks up in March; APA and EQT Most Shorted, COP Least Shorted
Investors Don't See Light At End Of Equillium, Inc.'s (NASDAQ:EQ) Tunnel And Push Stock Down 28%
The Equillium, Inc. (NASDAQ:EQ) share price has softened a substantial 28% over the previous 30 days, handing back much of the gains the stock has made lately. Of course, over the longer-term many
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on April 1, 2024, the Compensation
Buy Rating Affirmed for Equillium on Strong Clinical Data and Potential Financial Upsides
Equillium Is Maintained at Buy by HC Wainwright & Co.
Equillium Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Equillium, Raises Price Target to $5
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Equillium with a Buy and raises the price target from $4 to $5.
Equillium Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 138.1% HC Wainwright & Co. $4 → $5 Maintains Buy 12/26/2023 90.48% HC Wainwright & Co. $4.5 → $
Buy Rating Reaffirmed for Equillium on Strong Itolizumab Trial Results and Positive Financial Outlook
Equillium Announces Positive Topline Data From the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
Topline data delivered to Ono Pharmaceutical, representing the first of two data sets that will trigger Ono's option exercise decision for itolizumabItolizumab continues to show clinically meaningful
Buy Rating Affirmed for Equillium Amid Promising Clinical Trials and Potential Financial Upsides
Equillium Shares Fall After Swing to 4Q Loss
By Dean Seal Shares of Equillium fell after the company swung to a loss in the fourth quarter on lower sales. The stock was down 18% at $2 on Tuesday. Shares have more than doubled since the start o
VERI, CHEK and CZOO Among Mid-day Movers
Equillium: Q4 Earnings Insights
Equillium (NASDAQ:EQ) reported its Q4 earnings results on Monday, March 25, 2024 at 04:01 PM.Here's what investors need to know about the announcement.EarningsEquillium beat estimated earnings by 59.0
Equillium Swings to Q4 Loss As Revenue Falls
Equillium (EQ) reported a Q4 loss late Monday of $0.07 per diluted share, compared with net income of $0.08 a year earlier. Three analysts polled by Capital IQ expected a loss of $0.17. Revenue for th
Equillium Q4 2023 GAAP EPS $(0.07) Beats $(0.17) Estimate, Sales $9.200M Beat $6.425M Estimate
Equillium (NASDAQ:EQ) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.17) by 58.82 percent. The company reported quarterly sales of $9.200 million whic
Earnings Flash (EQ) EQUILLIUM Reports Q4 Revenue $9.2M
04:02 PM EDT, 03/25/2024 (MT Newswires) -- Earnings Flash (EQ) EQUILLIUM Reports Q4 Revenue $9.2M
Equillium 4Q Loss/Shr 7c >EQ
Equillium 4Q Loss/Shr 7c >EQ
Press Release: Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights $40.9 million cash balance at the end of 2023 expected to provide cash runway into 2H 20
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the H.C.
Individual Investors Account for 41% of Equillium, Inc.'s (NASDAQ:EQ) Ownership, While Insiders Account for 20%
Analysis
Price Target
No Data
